Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915442 · ClinicalTrials.gov registry record · Phase 2
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
A Phase 2 study of Oligometastatic Prostate Cancer, sponsored by Catherine Spina.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT05915442 is a Phase 2 study of Oligometastatic Prostate Cancer that is actively recruiting participants, run by Catherine Spina. The registered enrollment target is 23 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05915442, a Phase 2 study of Oligometastatic Prostate Cancer, is actively recruiting participants, sponsored by Catherine Spina.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progression-free survival (PFS), and hormone therapy-free survival and mitigate immunosuppressive changes to the tumor microenvironment (TME), compared to SBRT alone.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Etrumadenant
Study Locations (1)
New York
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05915442
The ClinicalTrials.gov registry entry for NCT05915442 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catherine Spina, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligometastatic Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT05915442 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05915442 about?
NCT05915442 is a clinical study titled "Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer". This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that...
What is the current status of trial NCT05915442?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2023-07-01. Estimated completion is 2028-12.
What conditions does trial NCT05915442 study?
This clinical trial studies the following conditions: Oligometastatic Prostate Cancer.
What interventions are being tested in trial NCT05915442?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Zimberelimab (DRUG), Quemliclustat (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT05915442?
This trial is sponsored by Catherine Spina, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05915442 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.